EBITDA margins are expected to improve by 156 bps to 19.9%. Net profit is expected to increase 11.66% QoQ to Rs 21 crore.

Shalby Ltd. key Products/Revenue Segments include Sale of services, Medicines and Other Operating Revenue for the year ending 31-Mar-2022.

Shalby Ltd., incorporated in the year 2004, is a Small Cap company (having a market cap of Rs 989.91 Crore) operating in Hospitals & Allied...

Covid-19 has cut short the expansion plans of private hospitals that have been reducing their capex in recent years.

Shalby has a debt free balance sheet, a unique feature among hospital chains, which are on expansion mode.

Hospital industry may be staring at an inflection point, analysts’ commentaries suggest.

Investors are now looking at hospitals as many large pharma cos are facing regulatory issues.

Illegal import of drugs from Bangladesh and other neighbouring countries have further added to the woes of pharmaceutical companies. Expert...

Investors took money off the table in light of weak global cues.

Govt should improvise on the price structure of Ayushman surgical packages in near future, says Shah

Competition from private equitybacked players also posed a risk to growth.

Buy Shalby Ltd. at a price target of Rs 275.

Shares of most midcap and smallcap stocks are under pressure this calendar.

Here is a list of top stocks that are likely to be in focus in today's trading session.

Nifty50 made a solid bullish candle on Thursday to settle above its immediate resistance level.

Here is a list of top stocks that are likely to be in focus in today's trading session.

Let’s check out what might influence Dalal Street all through the day.